多家上市藥企產品入圍新版醫保目錄市場格局或將重寫
格隆匯8月22日丨據上證報,據不完全統計,2019版《目錄》僅調入的西藥獨家品種就超過70個,糖尿病藥、降壓藥、神經系統藥物這三種慢性病藥物佔據了新調入西藥產品的70%以上。其中,進口藥物依然佔據六成以上。而在本土企業中,通化東寶、華邦健康全資子公司華邦製藥、甘李藥業、江蘇豪森等藥企則較有優勢。另據國家醫保局透露,目前已初步確定128個藥品納入擬談判准入範圍,包括109個西藥和19箇中成藥。這些藥品的治療領域主要涉及癌症、罕見病等重大疾病、丙肝、乙肝以及高血壓、糖尿病等慢性病等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.